Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus AUGMENTIN 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus AUGMENTIN 500.
AMPICILLIN TRIHYDRATE vs AUGMENTIN '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
Amoxicillin is a semisynthetic aminopenicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting cell wall integrity, leading to bacteriolysis. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates a broad range of beta-lactamases, preventing degradation of amoxicillin and extending its spectrum to include beta-lactamase-producing bacteria.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
1 tablet (amoxicillin 500 mg / clavulanate 125 mg) orally every 8 hours or 1 tablet (amoxicillin 875 mg / clavulanate 125 mg) orally every 12 hours for mild to moderate infections. For severe infections, use 875 mg/125 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
Amoxicillin: 1-1.3 hours; clavulanate: 1 hour. In renal impairment (CrCl <30 mL/min): amoxicillin 7-20 hours, clavulanate 4-6 hours. Extends dosing interval.
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Renal excretion 50-70% (amoxicillin) and 40-60% (clavulanate) as unchanged drug; tubular secretion and glomerular filtration. Fecal elimination <10%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic